Cure8 research brief
Findings suggest a dietary-derived prebiotic (Poria cocos polysaccharides) may reduce experimental colitis by shifting the microbiome and bile acids toward anti-inflammatory signaling—an avenue that could inform future microbiome-targeted therapies for UC.
Researchers studying microbiome–bile-acid interactions, basic-science clinicians interested in IBD mechanisms, and patients curious about prebiotics and microbiome research (note: preclinical evidence only).
PCP is a fungal polysaccharide studied here as a dietary/prebiotic intervention in experimental ulcerative colitis models. In mice and laboratory assays it promoted growth of P.
distasonis, increased bile salt hydrolase activity and certain secondary bile acids, and engaged TGR5-related signaling that the authors link to reduced inflammation and improved gut barrier/histology. This report is grounded in the article abstract and experimental models (mouse DSS colitis, in vitro growth assays, metabolomics).
It does not present human clinical trial data. It suggests a mechanistic pathway rather than clinical efficacy in patients. Practical point: the paper frames PCP as a candidate prebiotic to modulate the microbiome–bile acid–TGR5 axis; however, translation to human treatment remains untested in this report.
This is an abstract-level summary of preclinical work (mouse models and in vitro studies). The study does not provide human clinical data; effects in people, appropriate dosing, safety, and long-term outcomes are not addressed. that DSS mouse colitis and microbiome findings may not directly translate to human UC.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This research suggests a new, preclinical microbiome- and metabolite-based pathway (APA-1 → THDCA → TGR5/cAMP/PKA → NLRP3) that reduced inflammation in a mouse model of ulcerative colitis, which could guide future...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
People with ulcerative colitis may be interested because the study explores a way to boost curcumin’s activity and suggests gut microbiota changes could underlie protection against colitis.
